PT  - JOURNAL ARTICLE
AU  - Diaz, Lena M.
AU  - Johnson, Brandon E.
AU  - Jenkins, Daniel M.
TI  - Real-time optical analysis of a colorimetric LAMP assay for SARS-CoV-2 in saliva with a handheld instrument improves accuracy compared to endpoint assessment
AID  - 10.1101/2021.01.13.21249412
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.13.21249412
4099  - http://medrxiv.org/content/early/2021/01/15/2021.01.13.21249412.short
4100  - http://medrxiv.org/content/early/2021/01/15/2021.01.13.21249412.full
AB  - Controlling the course of the COVID-19 pandemic will require widespread deployment of consistent and accurate diagnostic testing of the novel coronavirus SARS-CoV-2. Ideally, tests should detect a minimum viral load, be minimally invasive, and provide a rapid and simple readout. Current FDA-approved RT-qPCR-based standard diagnostic approaches require invasive nasopharyngeal swabs and involve laboratory-based analyses that can delay results. Recently, a loop mediated isothermal nucleic acid amplification (LAMP) test that utilizes colorimetric readout received FDA approval. This approach utilizes a pH indicator dye to detect drop in pH from nucleotide hydrolysis during nucleic acid amplification. This method has only been approved for use with RNA extracted from clinical specimens collected via nasopharyngeal swabs. In this study, we developed a quantitative LAMP-based strategy to detect SARS-CoV-2 RNA in saliva. Our detection system distinguished positive from negative sample types using a handheld instrument that monitors optical changes throughout the LAMP reaction. We used this system in a streamlined LAMP testing protocol that could be completed in less than two hours to directly detect inactivated SARS-CoV-2 in minimally processed saliva that bypassed RNA extraction, with a limit of detection (LOD) of 50 genomes/reaction. The quantitative method correctly detected virus in 100% of contrived clinical samples spiked with inactivated SARS- CoV-2 at either 1X (50 genomes/reaction) or 2X (100 genomes/reaction) of the LOD. Importantly the quantitative method was based on dynamic optical changes during the reaction so was able to correctly classify samples that were misclassified by endpoint observation of color.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialno clinical trials were conductedFunding StatementWe would like to thank Dr. John M. Berestecky (Professor, Microbiology and Biotechnology, Kapiolani Community College, Honolulu, HI; Director of the Monoclonal Antibody Service Facility and Training Program) and Dr. Rebecca Kanenaka, (State Certified Microbiologist and CLIA Certified Lab Director, Kapiolani Community College Honolulu, HI) for their roles as project advisors, community outreach and assistance with IBC protocol certification and experimental design, as well as Dr. Reinhold Penner and Dr. Andrea Fleig for reagents and equipment. This project could not have been completed without the generous donation of colorimetric assay reagents from Nathan Tanner (New England Biolabs) who early on during the pandemic also shared LAMP primer sequences used in this study. This research is part of a global initiative, referred to as gLAMP, to validate LAMP diagnostics for the detection SARS-CoV-2 and we thank all participating members who helped guide our testing protocols from labs across the world. Finally, we express our gratitude to Diagenetix Inc. (Honolulu, HI) for use and deconstruction of commercial BioRanger units and for continued technical support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was waived by the Institutional Review Board - Human Studies Program of the University of Hawaii at Manoa. Based on the research study design, specifically where the samples used did not include identifiers/codes and researchers did not re-identify the samples/data, it was determined that this is Not Human Subjects Research and therefore does not require IRB approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used for this research is reported in the manuscript or Supplementary Material.